文献类型：期刊文献

英文题名：Prognostic significance of N6-methyladenosine-modified related chemotransferase METTL3 in gastric carcinoma: Evidence from meta-analysis

作者：Zhu, Chenglou[1];Wu, Qiong[1];Xu, Yan[2];Ma, Jichun[1];Hu, Yongli[1];Wang, Junhong[1];Gao, Zhenhua[3,6];Da, Mingxu[1,4,5]

第一作者：Zhu, Chenglou

通信作者：Da, M[1];Gao, ZH[2]

机构：[1]Lanzhou Univ, Sch Clin Med 1, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Peoples R China;[3]First Peoples Hosp Baiyin, Hepatobiliary Surg, Baiyin, Peoples R China;[4]Gansu Prov Hosp, Dept Surg Oncol, Lanzhou, Peoples R China;[5]Gansu Prov Hosp, Dept Surg Oncol, Lanzhou 730000, Gansu, Peoples R China;[6]First Peoples Hosp Baiyin, Hepatobiliary Surg, Baiyin 730900, Peoples R China

第一机构：Lanzhou Univ, Sch Clin Med 1, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Surg Oncol, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), First Peoples Hosp Baiyin, Hepatobiliary Surg, Baiyin 730900, Peoples R China.

年份：2023

卷号：38

期号：3-4

起止页码：185

外文期刊名：INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS

收录：;Scopus(收录号：2-s2.0-85164117545);WOS:【SCI-EXPANDED(收录号:WOS:001022357400001)】；

基金：The author(s) disclosed receipt of the followingfinancial supportfor the research, authorship, and/or publication of this article: Thiswork was supported by the Natural Science Foundation of Gansu Province, National Natural Science Foundation of China, (grantnumber 21CX6FD163, 22JR11RA252, 82160588)

语种：英文

外文关键词：Gastric carcinoma; N6-methyladenosine; methyltransferase-like3; prognostic biomarker; meta-analysis

摘要：Background: N6-methyladenosine (m(6)A) methylation is known as the research hotspot for tumor epimodification, and its associated methyltransferase-like3 (METTL3) is significantly differentially expressed in gastric carcinoma, but its clinical value has not been summarized. This meta-analysis aimed to evaluate the prognostic significance of METTL3 in gastric carcinoma.Material and methods: Databases, including PubMed, EMBASE (Ovid platform), Science Direct, Scopus, MEDLINE, Google Scholar, Web of Science, and Cochrane Library, were used to identify relevant eligible studies. The endpoints included overall survival, progression-free survival, recurrence-free survival, post-progression survival, and disease-free survival. Hazard ratios (HR) with 95% confidence intervals (CI) were used to correlate METTL3 expression with prognosis. Subgroup and sensitivity analyses were performed.Results: Seven eligible studies involving 3034 gastric carcinoma patients were recruited for this meta-analysis. The analysis showed that high METTL3 expression was associated with significantly poorer overall survival (HR = 2.37, 95% CI 1.66-3.39, P < 0.01) and unfavorable disease-free survival (HR = 2.58, 95% CI 1.97-3.38, P < 0.01), as did unfavorable progression-free survival (HR = 1.48, 95% CI 1.19-1.84, P < 0.01)/recurrence-free survival (HR = 2.62, 95% CI 1.93-5.62, P < 0.01)/post-progression survival (HR = 1.53, 95% CI 1.22-1.91, P < 0.01). Subgroup analysis found that high METTL3 expression was associated with worse overall survival in patients with Chinese (HR = 2.21, 95% CI 1.48-3.29, P < 0.01), in studies with sample source from formalin-fixed, paraffin-embedded tissues (HR = 2.66, 95% CI 1.79-3.94, P < 0.01), and the reported directly from articles group (HR = 2.42, 95% CI 1.66-3.53, P < 0.01). The subgroup analysis that was performed based on sample size, detected method, and follow-up showed the same results.Conclusions: High expression of METTL3 predicts poor prognosis in gastric carcinoma, indicating promise for METTL3 as a prognostic biomarker.